Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BU-FLU vs BU-CY-MEL Conditioning for HCT in Children With JMML
NCT01824693Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jun 2013
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 4
01
Overview
A Phase 2 trial of busulfan, cyclophosphamide, melphalan, fludarabine in juvenile myelomonocytic leukemia (JMML), sponsored by Children's Oncology Group. Started Jun 2013; status: completed.
02
Drugs
busulfancyclophosphamidemelphalanfludarabine
03
Conditions
juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT01824693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824693.